TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06404359

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise
Description: There will be 2 weekly sessions of 50 minutes, always guided by a physiotherapist, with the following distribution:~1.- Warm-up: 15 minutes of global exercises of strength and resistance, focusing on the areas that are going to be worked as a priority in that session.~Strength training: 6 to 8 strength exercises of large muscle groups. The approximate duration will be 25 minutes.~3.- Cool down / cool down: Combination of breathing exercises and stretching, 10 minutes.~Monitoring with activity bracelets.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Physical activity recommendations
Description: They will be provided with a physical activity plan to be followed on a weekly basis.
Study: NCT06612528

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: tDCS
Description: The tDCS is a non-invasive brain stimulation technique. In this study, we used an intensity of 2mA for 20 minutes in two different areas.~M1 group: the anode was over C5 (10-10 EEG system) and the cathode was placed over Fp2. For the Cerebellum group stimulation, the targeted anode area was 2 cm below the inion and the cathode over the deltoid muscle.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: tDCS
Description: The tDCS is a non-invasive brain stimulation technique. In this study, we used an intensity of 2mA for 20 minutes in two different areas.~M1 group: the anode was over C5 (10-10 EEG system) and the cathode was placed over Fp2. For the Cerebellum group stimulation, the targeted anode area was 2 cm below the inion and the cathode over the deltoid muscle.
Study: NCT06436690

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Diagnosis Mandate and Feedback
Description: The intervention consists of: a) a Refresher Training on AMR, (b) a Diagnosis Mandate, and (c) an Individualized Feedback.
Study: NCT05350527

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Consultation of a Web Platform
Description: Patients willing to participate in this research and randomized in the experimental arm will benefit, in addition to standard preoperative medical information, an access to the EDOP internet platform via personalized and secure access codes. They will be able to watch an explanatory video about breast surgery and find all the essential, practical and useful information about their intervention and the postoperative effects for the duration of their follow-up.
Study: NCT05574309

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Dissociation measure of pelvic and scapular girdles by inertial sensors of accelerometer
Description: Dissociation measure of pelvic and scapular girdles by 2 inertial sensors of accelerometer type (IMU BNO055) during a 10 m walking test

Intervention type: DEVICE
Group type: OTHER
Intervention: Dissociation measure of pelvic and scapular girdles by inertial sensors of accelerometer
Description: Dissociation measure of pelvic and scapular girdles by 2 inertial sensors of accelerometer type (IMU BNO055) during a 10 m walking test

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: GAITRite Device
Description: Walking parameter measured during a 10 m walking test with GaitRite device

Intervention type: DEVICE
Group type: OTHER
Intervention: GAITRite Device
Description: Walking parameter measured during a 10 m walking test with GaitRite device
Study: NCT06612528

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: tDCS
Description: The tDCS is a non-invasive brain stimulation technique. In this study, we used an intensity of 2mA for 20 minutes in two different areas.~M1 group: the anode was over C5 (10-10 EEG system) and the cathode was placed over Fp2. For the Cerebellum group stimulation, the targeted anode area was 2 cm below the inion and the cathode over the deltoid muscle.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Flexible tube in water
Description: The exercise involved producing sustained /u/ vowels in ascending and descending scales, tailored to each participants vocal range.~The flexible tube was 35 cm long, 1 cm in diameter, and 2 mm thick. One end of the tube was submerged 3 cm into a 500 ml bottle filled with water. Participants produced four sets of vocal exercises, each lasting 3 minutes, with 2-minute rests between sets, totaling 20 minutes of vocal therapy.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Flexible tube in water
Description: The exercise involved producing sustained /u/ vowels in ascending and descending scales, tailored to each participants vocal range.~The flexible tube was 35 cm long, 1 cm in diameter, and 2 mm thick. One end of the tube was submerged 3 cm into a 500 ml bottle filled with water. Participants produced four sets of vocal exercises, each lasting 3 minutes, with 2-minute rests between sets, totaling 20 minutes of vocal therapy.

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Flexible tube in water
Description: The exercise involved producing sustained /u/ vowels in ascending and descending scales, tailored to each participants vocal range.~The flexible tube was 35 cm long, 1 cm in diameter, and 2 mm thick. One end of the tube was submerged 3 cm into a 500 ml bottle filled with water. Participants produced four sets of vocal exercises, each lasting 3 minutes, with 2-minute rests between sets, totaling 20 minutes of vocal therapy.
Study: NCT02992756

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Growth Factors
Description: one dose 3-6 mL of PRP obtained by PRGF Endoret
Study: NCT06404255

Intervention type: BEHAVIORAL
Intervention: Stress management training
Description: Stress management training
Study: NCT04994808

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clofarabine
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Given IV

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Hematopoietic Cell Transplantation
Description: Undergo HCT

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Hematopoietic Cell Transplantation
Description: Undergo HCT

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Total-Body Irradiation
Description: Undergo TBI

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Total-Body Irradiation
Description: Undergo TBI

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treosulfan
Description: Given IV

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Echocardiography
Description: Undergo ECHO

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Echocardiography
Description: Undergo ECHO

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Multigated Acquisition Scan
Description: Undergo MUGA

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Multigated Acquisition Scan
Description: Undergo MUGA

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Lumbar Puncture
Description: Undergo lumbar puncture

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Lumbar Puncture
Description: Undergo lumbar puncture

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bone Marrow Aspiration
Description: Undergo bone marrow aspiration

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bone Marrow Aspiration
Description: Undergo bone marrow aspiration

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bone Marrow Biopsy
Description: Undergo bone marrow biopsy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bone Marrow Biopsy
Description: Undergo bone marrow biopsy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo collection of blood samples

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo collection of blood samples
Study: NCT05525000

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Validation
Description: The validation protocol consists of the following activities:~Activities of daily living, Exercise test on the treadmill, Exercise test on the cycle ergometer, Free-living session
Study: NCT05957861

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: web-based aerobic exercise
Description: Our designed AE program involved core muscle training through movements including marching, step touches, lunges, v-steps, box steps, twists, knee-ups, scoops, and scissors.
Study: NCT06128720

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Hyperbaric Oxygen
Description: Participant will undergo 60 minutes of Hyperbaric oxygen at 1.5ATA while breathing 100% oxygen

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Hyperbaric Oxygen
Description: Participant will undergo 60 minutes of Hyperbaric oxygen at 1.5ATA while breathing 100% oxygen

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Sham Hyperbaric Oxygen
Description: Participant will undergo 60 minutes of Sham Hyperbaric Oxygen at atmospheric pressure while breathing room air.
Study: NCT06402461

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness of the breath
Description: A 10 minute, audio guided, mindfulness of the breath meditation of the sort used in mindfulness-based cognitive therapy

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness of the breath
Description: A 10 minute, audio guided, mindfulness of the breath meditation of the sort used in mindfulness-based cognitive therapy

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness of sounds
Description: A 10 minute, audio guided, mindfulness of sounds meditation of the sort used in mindfulness-based cognitive therapy

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness of sounds
Description: A 10 minute, audio guided, mindfulness of sounds meditation of the sort used in mindfulness-based cognitive therapy

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Audiobook control
Description: Listening to a 10 minute extract from an audiobook
Study: NCT05018416

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Renal Autologous Cell Therapy (REACT)
Description: Autologous selected renal cells (SRC)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Renal Autologous Cell Therapy (REACT)
Description: Autologous selected renal cells (SRC)
Study: NCT05205928

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Outpatient therapy: 11 weeks of drug therapy with usual treatment + 4 weeks of closed-loop therapy
Description: The blinded drug will be used with participant's routine therapy (+ continuous glucose monitoring if not already in use) for 11 weeks with follow-up from qualified research personnel concerning pump settings, side effects, and incremental dose increase. While continuing to use the medication, there are 4 weeks of closed-loop pump therapy and drug use; glycemic outcomes will be taken from the last 4 weeks. This will be followed by laboratory and anthropometric testing, followed by 2 weeks of wash-out.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Outpatient therapy: 11 weeks of drug therapy with usual treatment + 4 weeks of closed-loop therapy
Description: The blinded drug will be used with participant's routine therapy (+ continuous glucose monitoring if not already in use) for 11 weeks with follow-up from qualified research personnel concerning pump settings, side effects, and incremental dose increase. While continuing to use the medication, there are 4 weeks of closed-loop pump therapy and drug use; glycemic outcomes will be taken from the last 4 weeks. This will be followed by laboratory and anthropometric testing, followed by 2 weeks of wash-out.
Study: NCT05781243

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lactated Ringer Solution
Description: Patients in the LR (Lactated Ringer solution) treatment arm will receive fluid therapy based on lactated Ringer's solution for a minimum of 48 hours.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Normal saline
Description: Patients in the NS (Normal Saline) treatment arm will receive fluid therapy based on lactated Ringer's solution for a minimum of 48 hours.
Study: NCT05399992

Intervention type: OTHER
Intervention: Inclisiran
Description: Prospective observational study. There is no treatment allocation. Patients who are receiving or intend to receive inclisiran are eligible to enroll into this study.
Study: NCT04829604

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ARX788
Description: The active pharmaceutical ingredient in ARX788 is an antibody drug conjugate (ADC) consisting of a humanized anti-HER2 monoclonal antibody (mAb) (IgG1κ) covalently conjugated to two microtubule-disrupting payloads AS269
Study: NCT06352437

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 3034701
Description: BI 3034701

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 3034701
Description: BI 3034701

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 3034701
Description: BI 3034701

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 3034701
Description: BI 3034701

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 3034701
Description: BI 3034701

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 3034701
Description: BI 3034701

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 3034701
Description: BI 3034701

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 3034701
Description: BI 3034701

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 3034701
Description: BI 3034701

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 3034701
Description: BI 3034701

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 3034701
Description: BI 3034701

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 3034701
Description: BI 3034701

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo matching BI 3034701
Description: Placebo matching BI 3034701

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo matching BI 3034701
Description: Placebo matching BI 3034701
Study: NCT05264714

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rimegepant
Description: 150 mg oral disintegrating tablet every other day for one week
Study: NCT06002789

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MSI-H/MSS (dMMR/pMMR) mixed sMPCC: combination of mFOLFOX6+PD-1 monoclonal antibody neoadjuvant therapy
Description: For MSI-H/MSS (dMMR/pMMR) mixed sMPCC, a combination of neoadjuvant chemotherapy with mFOLFOX6 and immunotherapy with PD-1 monoclonal antibody are applied.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: All-MSI-H (dMMR) sMPCC: single-drug PD-1 monoclonal antibody neoadjuvant therapy
Description: For all-MSI-H (dMMR) sMPCC, single-drug PD-1 monoclonal antibody immunotherapy is applied.
Study: NCT06188936

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ExSeed®
Description: In work package 3, participants will use the provided ExSeed® device and associated app downloaded onto their smartphone to analyse a semen sample provided at home. The app gives a result of normal or below normal, as well as an exact value for sperm concentration, progressive motility, and total motile sperm count. The patient will send their semen analysis results from the smartphone to the research team via secure email.

Intervention type: OTHER
Group type: OTHER
Intervention: Survey
Description: Surveys will be completed on a hard copy or electronically.

Intervention type: OTHER
Group type: OTHER
Intervention: Survey
Description: Surveys will be completed on a hard copy or electronically.
Study: NCT04774068

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Parsaclisib
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Romidepsin
Description: Given IV
Study: NCT06504446

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NOC-110
Description: Inhalation powder

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NOC-110
Description: Inhalation powder

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NOC-110
Description: Inhalation powder

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Inhalation powder
Study: NCT05557409

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AXS-05
Description: AXS-05 tablets, taken twice daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo tablets, taken twice daily
Study: NCT05874037

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluvoxamine
Description: Fluvoxamine is an FDA approved drug for the treatment of OCD. This trial is testing the effects of the drug on long COVID.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Fluvoxamine
Description: Fluvoxamine is an FDA approved drug for the treatment of OCD. This trial is testing the effects of the drug on long COVID.
Study: NCT06074666

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CareMeds Intervention
Description: 3 parenting sessions will be offered during weeks 2 through 4 of the study period.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Usual Care Group
Description: 3 parenting sessions will be offered during weeks 13 through 15 of the study period.
Study: NCT06199726

Intervention type: BEHAVIORAL
Intervention: REFLECT web-based tool
Description: Partnering with Nest Genomics, Investigators have developed a customizable web-based tool to support AYA patients through their cancer diagnosis journey for topics related to future family building and genetics. This interactive tool will include educational content to organize knowledge, make connections between concepts, and will include web links to more in-depth content and embedded videos. The interface will allow users to document questions that would be helpful in provider discussions and include decision support to assist with determining values and needs for proceeding with consultations related to genetic counseling and testing, and fertility.

Intervention type: BEHAVIORAL
Intervention: REFLECT web-based tool
Description: Partnering with Nest Genomics, Investigators have developed a customizable web-based tool to support AYA patients through their cancer diagnosis journey for topics related to future family building and genetics. This interactive tool will include educational content to organize knowledge, make connections between concepts, and will include web links to more in-depth content and embedded videos. The interface will allow users to document questions that would be helpful in provider discussions and include decision support to assist with determining values and needs for proceeding with consultations related to genetic counseling and testing, and fertility.
Study: NCT06472973

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Post-transplant addiction intervention
Description: The first addiction consultation will be conducted using the BRENDA method which allows the addiction specialist to carry out a psychosocial assessment, to entrust the results of this assessment to the participant, to answer their questions and to evaluate their reactions. Risk factors for alcohol relapse will be collected: social determinants, male gender, psychiatric comorbidities, duration of alcohol abstinence before LT(≥ or \< 6 months) and young age (\< 40 years). If the addiction specialist notes the presence of at least 3 risk factors for alcohol relapse, targeted addiction follow-up will be proposed to the participant including outpatient consultations with motivational interview at least every 4 weeks +/- pharmacological treatment of alcohol use disorder.In case of alcohol relapse or a period of high vulnerability to relapse, specific hospitalizations can be scheduled. If the participant has \<3 risk factors, an addictology consultation every 6 months at most will be proposed.
Study: NCT06219941

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD0901
Description: Antibody-drug conjugate/Biologic

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD0901
Description: Antibody-drug conjugate/Biologic

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD0901
Description: Antibody-drug conjugate/Biologic
Study: NCT06007495

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Investigational full-face mask with expiratory washout
Description: With cross-over in randomized order, mask worn for 30 minutes with prescribed single-limb non-invasive ventilation

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional full-face mask - single-limb
Description: With cross-over in randomized order, conventional mask such as RT077, worn for 30 minutes with prescribed single-limb non-invasive ventilation

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional full-face mask - dual-limb
Description: With cross-over in randomized order, conventional mask such as RT076, worn for 30 minutes with prescribed dual-limb non-invasive ventilation
Study: NCT05212584

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CD7CAR T cells
Description: CD7 CAR T cells are used to treat patients. Patient will be administered either fresh or thawed CAR T cells by IV injection after receiving lymphodepleting chemotherapy.
Study: NCT05341050

Intervention type: DRUG
Intervention: TKI
Description: halve dose of 2G-TKI for 12 months and then withdrawal for 12 months
Study: NCT06219941

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-Fluorouracil
Description: Chemotherapy agents

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leucovorin
Description: Chemotherapy agents

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: l-leucovorin
Description: Chemotherapy agents

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan
Description: Chemotherapy agents

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nanoliposomal Irinotecan
Description: Chemotherapy agents

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Chemotherapy agents
Study: NCT05754216

Intervention type: DEVICE
Group type: OTHER
Intervention: Nerve stimulation using nerve stimulation device and sterile wire electrode.
Description: A nerve stimulator device will be used in this study as a research tool to investigate whether a future (currently nonexistent) medical device might be able to stimulate desired pharyngeal musculature in a therapeutic manner.
Study: NCT06130540

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Secukinumab
Description: Intravenous (i.v.) doses of Secukinumab at Week 0, Week 4 and Week 8

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Secukinumab
Description: Intravenous (i.v.) doses of Secukinumab at Week 0, Week 4 and Week 8
Study: NCT06388200

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: Sub-Retinal Administration of OCU400-301
Description: Sub-Retinal Administration of OCU400-301

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: Sub-Retinal Administration of OCU400-301
Description: Sub-Retinal Administration of OCU400-301